TICAGRELOR
ANTIPLATELET DRUGS-EXCLUDING ASA 325 MG AND BELOW · MYOCARDIAL REINFARCTION PREVENTION ·+4
APHENA PHARMA S
Drug class
Antiplatelet and Antithrombotic Drugs (Selected Group 2)
The phrase "Antiplatelet and Antithrombotic Drugs (Selected Group 2)" does not represent a standard, recognized clinical or pharmacological therapeutic class in official medical compendia, FDA Established Pharmacologic Class listings, or major clinical guidelines. Read more about Antiplatelet and Antithrombotic Drugs (Selected Group 2)
104 drugs in this class 73 manufacturers
Drugs in Antiplatelet and Antithrombotic Drugs (Selected Group 2)
CILOSTAZOL
INTERMITTENT CLAUDICATION AGENTS · INTERMITTENT CLAUDICATION
CHARTWELL RX LL
TICAGRELOR
ANTIPLATELET DRUGS-EXCLUDING ASA 325 MG AND BELOW · MYOCARDIAL REINFARCTION PREVENTION ·+4
Mylan Pharmaceuticals
TICAGRELOR
ANTIPLATELET DRUGS-EXCLUDING ASA 325 MG AND BELOW · MYOCARDIAL REINFARCTION PREVENTION ·+4
SCIEGEN PHARMAC
TICAGRELOR
ANTIPLATELET DRUGS-EXCLUDING ASA 325 MG AND BELOW · MYOCARDIAL REINFARCTION PREVENTION ·+4
BIONPHARMA INC.
TICAGRELOR
ANTIPLATELET DRUGS-EXCLUDING ASA 325 MG AND BELOW · MYOCARDIAL REINFARCTION PREVENTION ·+4
RADHA PHARMACEU
TICAGRELOR
ANTIPLATELET DRUGS-EXCLUDING ASA 325 MG AND BELOW · MYOCARDIAL REINFARCTION PREVENTION ·+4
MACLEODS PHARMA
TICAGRELOR
ANTIPLATELET DRUGS-EXCLUDING ASA 325 MG AND BELOW · MYOCARDIAL REINFARCTION PREVENTION ·+4
AVPAK
TICAGRELOR
ANTIPLATELET DRUGS-EXCLUDING ASA 325 MG AND BELOW · MYOCARDIAL REINFARCTION PREVENTION ·+4
AHP
Filter & compare in the drug finder →
Opens the drug finder with Antiplatelet and Antithrombotic Drugs (Selected Group 2) preselected. Add indication or manufacturer filters there.
The phrase "Antiplatelet and Antithrombotic Drugs (Selected Group 2)" does not represent a standard, recognized clinical or pharmacological therapeutic class in official medical compendia, FDA Established Pharmacologic Class listings, or major clinical guidelines.
Instead, it reflects an administrative, institutional, or formulary-specific grouping rather than an established physiological classification.
Broadly, antithrombotic and antiplatelet agents prevent pathologic vascular thrombosis by inhibiting platelet activation, aggregation, or components of the coagulation cascade.
Clinically, these agents are utilized to prevent and manage thromboembolic conditions, including acute coronary syndromes, ischemic stroke, transient ischemic attacks, and deep vein thrombosis.
-
fda.gov
The phrase "Antiplatelet and Antithrombotic Drugs (Selected Group 2)" does not represent a standard, recognized clinical or pharmacological therapeutic class in official medical compendia, FDA Established Pharmacologic Class listings, or major clinical guidelines Instead, it reflects an administrative, institutional, or formulary-specific grouping rather than an established physiological classification
-
nih.gov
The phrase "Antiplatelet and Antithrombotic Drugs (Selected Group 2)" does not represent a standard, recognized clinical or pharmacological therapeutic class in official medical compendia, FDA Established Pharmacologic Class listings, or major clinical guidelines
-
chicagoems.org
Broadly, antithrombotic and antiplatelet agents prevent pathologic vascular thrombosis by inhibiting platelet activation, aggregation, or components of the coagulation cascade
-
clevelandclinic.org
Broadly, antithrombotic and antiplatelet agents prevent pathologic vascular thrombosis by inhibiting platelet activation, aggregation, or components of the coagulation cascade
-
fda.gov
Clinically, these agents are utilized to prevent and manage thromboembolic conditions, including acute coronary syndromes, ischemic stroke, transient ischemic attacks, and deep vein thrombosis
-
medlineplus.gov
Clinically, these agents are utilized to prevent and manage thromboembolic conditions, including acute coronary syndromes, ischemic stroke, transient ischemic attacks, and deep vein thrombosis
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.